Treatment
Ponatinib clinical trials
We’re tracking 13 recruiting studies that include Ponatinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06061094RecruitingPhase 2
Ph+ ALL chemo with targeted pills and transplant
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
AachenAges 18–65 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Birmingham, AlabamaAges 18 years+ - NCT06207123RecruitingPhase 1/Phase 2
New drug combo for T-cell leukemia or lymphoma
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
Chicago, IllinoisAges 18 years+ - NCT03934372RecruitingPhase 1/Phase 2
Ponatinib for children with relapsed or hard-to-treat cancers
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
GhentAges 1–17 - NCT07224100RecruitingPhase 2
Chemo plus targeted drug for newly diagnosed Ph+ ALL
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
Seattle, WashingtonAges 18 years+ - NCT01746836RecruitingPhase 2
Ponatinib for CML that didn’t respond to prior pills
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
Houston, TexasAges 18 years+ - NCT03263572RecruitingPhase 2
Study medicines for Philadelphia-positive ALL or relapsed leukemia
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Houston, TexasAges 18 years+ - NCT04747912RecruitingPhase 2
Chemotherapy-free early treatment for Ph+ ALL using inotuzumab
This Phase 2 trial tests a treatment strategy for newly diagnosed Ph+ B-cell acute lymphoblastic leukemia (ALL) that avoids traditional chemotherapy during the early “induction” phase, using inotuzumab ozogamicin instead. If it works, it could help control the leukemia while reducing exposure to chemotherapy early on.
Chicago, IllinoisAges 18 years+ - NCT06119269Recruiting
Ponatinib for chronic phase CML
This study looks at how the drug ponatinib works in people with chronic phase CML. It aims to understand how the body handles the drug and if it helps control the leukemia.
CagliariAges 18 years+ - NCT06390306Recruiting
Combination therapy for advanced CML
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06514534RecruitingPhase 2
Asciminib for CML with T315I mutation and ponatinib problems
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
BordeauxAges 18–99 - NCT06813079RecruitingPhase 2
Using tumor models to find your best treatment
This trial uses a personalized approach where a sample of your tumor is grown in the lab to test which drugs might work best for you. It is for people with advanced pancreatic cancer that cannot be surgically removed.
Toronto, OntarioAges 18 years+ - NCT06860269RecruitingPhase 2/Phase 3
New immune therapy and stem cell transplant for acute lymphoblastic leukemia
This study tests adding new immunotherapy drugs and possibly a stem cell transplant to the first treatment for adults with acute lymphoblastic leukemia (ALL). The goal is to see if these approaches help people live longer without the cancer coming back.
ParisAges 18–65
What Ponatinib is being studied for
Conditions with recruiting Ponatinib studies.
- Acute Lymphoblastic Leukemia
- Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Philadelphia Chromosome Positive
- Recurrent Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
Common questions
- Are there clinical trials studying Ponatinib?
- Yes. Clin2 currently lists 13 recruiting studies that include Ponatinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ponatinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ponatinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ponatinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.